Jefferies Highlights Revolution Medicines, Inc. (RVMD)’s RAS(ON) Platform in Coverage Initiation
TheFly reported on March 16 that Jefferies initiated coverage of RVMD with a Buy rating and set a price target of $140, up from $88.
Revolution Medicines Inc. (RVMD)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Farallon Capital Thomas Steyer | 14,582,796 | $1,161,519,701 | -1% | 5.48% |
| 2. | Baker Bros. Advisors Julian Baker And Felix Baker | 9,455,357 | $753,119,185 | 4.41% | |
| 3. | Paradigm Biocapital Advisors Senai Asefaw | 6,644,403 | $529,226,699 | +7% | 13.51% |
| 4. | Biotechnology Value Fund / BVF Inc Mark Lampert | 3,356,782 | $267,367,686 | -16% | 9% |
| 5. | Deerfield Management James E. Flynn | 2,894,613 | $230,555,925 | -21% | 2.94% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $46.00 | 760,869 | $34,999,974.00 | 760,869 | 2024-12-05 | Filing | |
| $46.00 | 543,478 | $24,999,988.00 | 2,096,612 | 2024-12-05 | Filing | |
| $20.85 | 6,200 | $129,270.00 | 1,553,134 | 2023-03-10 | Filing | |
| $20.43 | 93,800 | $1,916,334.00 | 1,546,934 | 2023-03-10 | Filing | |
| $22.00 | 318,181 | $6,999,982.00 | 618,181 | 2023-03-07 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $97.21 | 400 | $38,882.84 | 54,400 | 2026-03-25 | Filing | |
| $96.43 | 11,036 | $1,064,200.38 | 54,800 | 2026-03-25 | Filing | |
| $95.49 | 21,086 | $2,013,415.69 | 65,836 | 2026-03-25 | Filing | |
| $94.16 | 3,128 | $294,520.28 | 86,922 | 2026-03-25 | Filing | |
| $93.22 | 1,800 | $167,801.40 | 90,050 | 2026-03-25 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 40,231 | $3,892,349 | 0.13% | |
| 2. | 33,633 | $3,270,810 | 0.04% | |
| 3. | 3,327 | $323,551 | 0.01% | |
| 4. | 1,599 | $155,503 | 0.01% | |
| 5. | 968 | $95,484 | 0% |
News See All
13 Best Stocks to Invest In on Robinhood for Beginners
MacroMicro reports that as of March 18, 2026, the S&P 500's forward 12-month P/E was 21.35, which was far higher than its 10-year historical average of 18.9 but slightly lower than the 22.0x reported ...
Is Revolution Medicines, Inc. (RVMD) A Good Stock To Buy Now?
Is RVMD a good stock to buy? We came across a bullish thesis on Revolution Medicines, Inc. on Two Natural Capital’s Substack.
Revolution Medicines, Inc. (RVMD) Net Loss Widens amid Progress on Clinical Trial Programs
Revolution Medicines, Inc. (NASDAQ:RVMD) is one of the best cancer stocks to invest in now. On February 26, Revolution Medicines, Inc. (NASDAQ:RVMD) CEO Mark A.
11 Best Cancer Stocks to Invest In Now
Pharmaceutical companies are a blend of defensive income plays and growth opportunities.
Revolution Medicines, Inc. (NASDAQ:RVMD) Q4 2025 Earnings Call Transcript
Revolution Medicines, Inc. (NASDAQ:RVMD) Q4 2025 Earnings Call Transcript February 25, 2026Revolution Medicines, Inc. misses on earnings expectations.
Evercore ISI Initiates Revolution Medicines (RVMD) With an Outperform Rating - Here's Why
Revolution Medicines, Inc. (NASDAQ:RVMD) is one of the best strong buy healthcare stocks to invest in. Revolution Medicines, Inc.
11 Best Strong Buy Healthcare Stocks to Invest In
On February 23, Steven Wieting, CIO Group chief investment strategist, appeared on CNBC’s ‘The Exchange’ to talk about the stock market and the recent price action in stocks.
Has Revolution Medicines (RVMD) Found a Breakthrough in Cancer Treatment?
Aristotle Funds, an investment advisor, released its “Growth Equity Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. U.S.
JPMorgan Signals High Conviction Ahead of Revolution Medicines (RVMD) Readout
JPMorgan added Overweight-rated Revolution Medicines Inc. (NASDAQ:RVMD) to its “Positive Catalyst Watch” list as per a February 17 report.
Hedge Fund Resource Center